XBI holdings
State Street SPDR S&P Biotech ETF
Positions
161 stored of 161 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors State Street Navigator Securities Lending Portfolio II | US8574927062 | 857492706 | 5.875% | $630.6M | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 2 | Apogee Therapeutics Inc | US03770N1019 | 03770N101 | 1.488% | $159.8M | Equity (common) | Corporate | United States | USD |
| 3 | Moderna Inc | US60770K1079 | 60770K107 | 1.412% | $151.6M | Equity (common) | Corporate | United States | USD |
| 4 | Twist Bioscience Corp | US90184D1000 | 90184D100 | 1.408% | $151.1M | Equity (common) | Corporate | United States | USD |
| 5 | Oruka Therapeutics Inc | US6876041087 | 687604108 | 1.379% | $148.0M | Equity (common) | Corporate | United States | USD |
| 6 | Kymera Therapeutics Inc | US5015751044 | 501575104 | 1.360% | $145.9M | Equity (common) | Corporate | United States | USD |
| 7 | Viking Therapeutics Inc | US92686J1060 | 92686J106 | 1.304% | $140.0M | Equity (common) | Corporate | United States | USD |
| 8 | Praxis Precision Medicines Inc | US74006W2070 | 74006W207 | 1.290% | $138.5M | Equity (common) | Corporate | United States | USD |
| 9 | Erasca Inc | US29479A1088 | 29479A108 | 1.271% | $136.4M | Equity (common) | Corporate | United States | USD |
| 10 | Revolution Medicines Inc | US76155X1000 | 76155X100 | 1.205% | $129.3M | Equity (common) | Corporate | United States | USD |
| 11 | Rhythm Pharmaceuticals Inc | US76243J1051 | 76243J105 | 1.202% | $129.0M | Equity (common) | Corporate | United States | USD |
| 12 | CG oncology Inc | US1569441009 | 156944100 | 1.200% | $128.8M | Equity (common) | Corporate | United States | USD |
| 13 | SELLAS Life Sciences Group Inc | US81642T2096 | 81642T209 | 1.190% | $127.7M | Equity (common) | Corporate | United States | USD |
| 14 | Vaxcyte Inc | US92243G1085 | 92243G108 | 1.187% | $127.4M | Equity (common) | Corporate | United States | USD |
| 15 | Dianthus Therapeutics Inc | US2528281080 | 252828108 | 1.183% | $127.0M | Equity (common) | Corporate | United States | USD |
| 16 | Cytokinetics Inc | US23282W6057 | 23282W605 | 1.178% | $126.5M | Equity (common) | Corporate | United States | USD |
| 17 | Natera Inc | US6323071042 | 632307104 | 1.163% | $124.8M | Equity (common) | Corporate | United States | USD |
| 18 | Scholar Rock Holding Corp | US80706P1030 | 80706P103 | 1.157% | $124.2M | Equity (common) | Corporate | United States | USD |
| 19 | Roivant Sciences Ltd | BMG762791017 | Not reported | 1.155% | $124.0M | Equity (common) | Corporate | Bermuda | USD |
| 20 | Mirum Pharmaceuticals Inc | US6047491013 | 604749101 | 1.155% | $124.0M | Equity (common) | Corporate | United States | USD |
| 21 | Cogent Biosciences Inc | US19240Q2012 | 19240Q201 | 1.144% | $122.8M | Equity (common) | Corporate | United States | USD |
| 22 | Ultragenyx Pharmaceutical Inc | US90400D1081 | 90400D108 | 1.141% | $122.4M | Equity (common) | Corporate | United States | USD |
| 23 | Travere Therapeutics Inc | US89422G1076 | 89422G107 | 1.127% | $121.0M | Equity (common) | Corporate | United States | USD |
| 24 | Alkermes PLC | IE00B56GVS15 | Not reported | 1.109% | $119.0M | Equity (common) | Corporate | Ireland | USD |
| 25 | Krystal Biotech Inc | US5011471027 | 501147102 | 1.104% | $118.5M | Equity (common) | Corporate | United States | USD |
| 26 | Celcuity Inc | US15102K1007 | 15102K100 | 1.100% | $118.0M | Equity (common) | Corporate | United States | USD |
| 27 | Relay Therapeutics Inc | US75943R1023 | 75943R102 | 1.099% | $118.0M | Equity (common) | Corporate | United States | USD |
| 28 | Spyre Therapeutics Inc | US00773J2024 | 00773J202 | 1.097% | $117.7M | Equity (common) | Corporate | United States | USD |
| 29 | TG Therapeutics Inc | US88322Q1085 | 88322Q108 | 1.093% | $117.3M | Equity (common) | Corporate | United States | USD |
| 30 | Beam Therapeutics Inc | US07373V1052 | 07373V105 | 1.079% | $115.9M | Equity (common) | Corporate | United States | USD |
| 31 | Insmed Inc | US4576693075 | 457669307 | 1.076% | $115.5M | Equity (common) | Corporate | United States | USD |
| 32 | Protagonist Therapeutics Inc | US74366E1029 | 74366E102 | 1.075% | $115.4M | Equity (common) | Corporate | United States | USD |
| 33 | Arrowhead Pharmaceuticals Inc | US04280A1007 | 04280A100 | 1.069% | $114.7M | Equity (common) | Corporate | United States | USD |
| 34 | Vera Therapeutics Inc | US92337R1014 | 92337R101 | 1.059% | $113.7M | Equity (common) | Corporate | United States | USD |
| 35 | Vertex Pharmaceuticals Inc | US92532F1003 | 92532F100 | 1.057% | $113.5M | Equity (common) | Corporate | United States | USD |
| 36 | Madrigal Pharmaceuticals Inc | US5588681057 | 558868105 | 1.057% | $113.4M | Equity (common) | Corporate | United States | USD |
| 37 | AbbVie Inc | US00287Y1091 | 00287Y109 | 1.038% | $111.4M | Equity (common) | Corporate | United States | USD |
| 38 | Biogen Inc | US09062X1037 | 09062X103 | 1.032% | $110.7M | Equity (common) | Corporate | United States | USD |
| 39 | PTC Therapeutics Inc | US69366J2006 | 69366J200 | 1.031% | $110.7M | Equity (common) | Corporate | United States | USD |
| 40 | Halozyme Therapeutics Inc | US40637H1095 | 40637H109 | 1.030% | $110.5M | Equity (common) | Corporate | United States | USD |
| 41 | uniQure NV | NL0010696654 | Not reported | 1.028% | $110.4M | Equity (common) | Corporate | Netherlands | USD |
| 42 | Bridgebio Pharma Inc | US10806X1028 | 10806X102 | 1.025% | $110.0M | Equity (common) | Corporate | United States | USD |
| 43 | CRISPR Therapeutics AG | CH0334081137 | Not reported | 1.023% | $109.8M | Equity (common) | Corporate | Switzerland | USD |
| 44 | ImmunityBio Inc | US45256X1037 | 45256X103 | 1.019% | $109.4M | Equity (common) | Corporate | United States | USD |
| 45 | Summit Therapeutics Inc | US86627T1088 | 86627T108 | 1.012% | $108.6M | Equity (common) | Corporate | United States | USD |
| 46 | Ionis Pharmaceuticals Inc | US4622221004 | 462222100 | 1.003% | $107.7M | Equity (common) | Corporate | United States | USD |
| 47 | Incyte Corp | US45337C1027 | 45337C102 | 0.998% | $107.1M | Equity (common) | Corporate | United States | USD |
| 48 | Amgen Inc | US0311621009 | 031162100 | 0.995% | $106.8M | Equity (common) | Corporate | United States | USD |
| 49 | Neurocrine Biosciences Inc | US64125C1099 | 64125C109 | 0.972% | $104.3M | Equity (common) | Corporate | United States | USD |
| 50 | Gilead Sciences Inc | US3755581036 | 375558103 | 0.965% | $103.5M | Equity (common) | Corporate | United States | USD |
| 51 | Regeneron Pharmaceuticals Inc | US75886F1075 | 75886F107 | 0.961% | $103.2M | Equity (common) | Corporate | United States | USD |
| 52 | Exelixis Inc | US30161Q1040 | 30161Q104 | 0.960% | $103.0M | Equity (common) | Corporate | United States | USD |
| 53 | Alnylam Pharmaceuticals Inc | US02043Q1076 | 02043Q107 | 0.959% | $102.9M | Equity (common) | Corporate | United States | USD |
| 54 | BioMarin Pharmaceutical Inc | US09061G1013 | 09061G101 | 0.945% | $101.4M | Equity (common) | Corporate | United States | USD |
| 55 | ACADIA Pharmaceuticals Inc | US0042251084 | 004225108 | 0.937% | $100.6M | Equity (common) | Corporate | United States | USD |
| 56 | Nuvalent Inc | US6707031075 | 670703107 | 0.929% | $99.7M | Equity (common) | Corporate | United States | USD |
| 57 | Immunovant Inc | US45258J1025 | 45258J102 | 0.925% | $99.3M | Equity (common) | Corporate | United States | USD |
| 58 | United Therapeutics Corp | US91307C1027 | 91307C102 | 0.924% | $99.2M | Equity (common) | Corporate | United States | USD |
| 59 | Intellia Therapeutics Inc | US45826J1051 | 45826J105 | 0.907% | $97.4M | Equity (common) | Corporate | United States | USD |
| 60 | GRAIL Inc | US3847471014 | 384747101 | 0.907% | $97.3M | Equity (common) | Corporate | United States | USD |
| 61 | BioCryst Pharmaceuticals Inc | US09058V1035 | 09058V103 | 0.893% | $95.8M | Equity (common) | Corporate | United States | USD |
| 62 | Catalyst Pharmaceuticals Inc | US14888U1016 | 14888U101 | 0.874% | $93.8M | Equity (common) | Corporate | United States | USD |
| 63 | Dyne Therapeutics Inc | US26818M1080 | 26818M108 | 0.859% | $92.2M | Equity (common) | Corporate | United States | USD |
| 64 | Tango Therapeutics Inc | US87583X1090 | 87583X109 | 0.842% | $90.4M | Equity (common) | Corporate | United States | USD |
| 65 | Denali Therapeutics Inc | US24823R1059 | 24823R105 | 0.833% | $89.4M | Equity (common) | Corporate | United States | USD |
| 66 | Veracyte Inc | US92337F1075 | 92337F107 | 0.819% | $87.9M | Equity (common) | Corporate | United States | USD |
| 67 | Ideaya Biosciences Inc | US45166A1025 | 45166A102 | 0.804% | $86.3M | Equity (common) | Corporate | United States | USD |
| 68 | Recursion Pharmaceuticals Inc | US75629V1044 | 75629V104 | 0.757% | $81.2M | Equity (common) | Corporate | United States | USD |
| 69 | Sarepta Therapeutics Inc | US8036071004 | 803607100 | 0.747% | $80.2M | Equity (common) | Corporate | United States | USD |
| 70 | Arcus Biosciences Inc | US03969F1093 | 03969F109 | 0.743% | $79.8M | Equity (common) | Corporate | United States | USD |
| 71 | Syndax Pharmaceuticals Inc | US87164F1057 | 87164F105 | 0.718% | $77.1M | Equity (common) | Corporate | United States | USD |
| 72 | Arcutis Biotherapeutics Inc | US03969K1088 | 03969K108 | 0.712% | $76.4M | Equity (common) | Corporate | United States | USD |
| 73 | Mineralys Therapeutics Inc | US6031701013 | 603170101 | 0.709% | $76.1M | Equity (common) | Corporate | United States | USD |
| 74 | Celldex Therapeutics Inc | US15117B2025 | 15117B202 | 0.702% | $75.4M | Equity (common) | Corporate | United States | USD |
| 75 | Agios Pharmaceuticals Inc | US00847X1046 | 00847X104 | 0.693% | $74.4M | Equity (common) | Corporate | United States | USD |
| 76 | Viridian Therapeutics Inc | US92790C1045 | 92790C104 | 0.671% | $72.1M | Equity (common) | Corporate | United States | USD |
| 77 | Novavax Inc | US6700024010 | 670002401 | 0.661% | $70.9M | Equity (common) | Corporate | United States | USD |
| 78 | Disc Medicine Inc | US2546041011 | 254604101 | 0.653% | $70.1M | Equity (common) | Corporate | United States | USD |
| 79 | ADMA Biologics Inc | US0008991046 | 000899104 | 0.608% | $65.2M | Equity (common) | Corporate | United States | USD |
| 80 | Immunome Inc | US45257U1088 | 45257U108 | 0.591% | $63.4M | Equity (common) | Corporate | United States | USD |
| 81 | Palvella Therapeutics Inc | US6979471090 | 697947109 | 0.582% | $62.5M | Equity (common) | Corporate | United States | USD |
| 82 | Iovance Biotherapeutics Inc | US4622601007 | 462260100 | 0.562% | $60.3M | Equity (common) | Corporate | United States | USD |
| 83 | Absci Corp | US00091E1091 | 00091E109 | 0.558% | $59.9M | Equity (common) | Corporate | United States | USD |
| 84 | Nurix Therapeutics Inc | US67080M1036 | 67080M103 | 0.556% | $59.7M | Equity (common) | Corporate | United States | USD |
| 85 | Kodiak Sciences Inc | US50015M1099 | 50015M109 | 0.543% | $58.3M | Equity (common) | Corporate | United States | USD |
| 86 | Biohaven Ltd | VGG1110E1079 | Not reported | 0.525% | $56.4M | Equity (common) | Corporate | British Virgin Islands | USD |
| 87 | Vericel Corp | US92346J1088 | 92346J108 | 0.495% | $53.1M | Equity (common) | Corporate | United States | USD |
| 88 | AnaptysBio Inc | US0327241065 | 032724106 | 0.495% | $53.1M | Equity (common) | Corporate | United States | USD |
| 89 | Capricor Therapeutics Inc | US14070B3096 | 14070B309 | 0.489% | $52.5M | Equity (common) | Corporate | United States | USD |
| 90 | Stoke Therapeutics Inc | US86150R1077 | 86150R107 | 0.480% | $51.5M | Equity (common) | Corporate | United States | USD |
| 91 | Monte Rosa Therapeutics Inc | US61225M1027 | 61225M102 | 0.477% | $51.2M | Equity (common) | Corporate | United States | USD |
| 92 | Vir Biotechnology Inc | US92764N1028 | 92764N102 | 0.469% | $50.4M | Equity (common) | Corporate | United States | USD |
| 93 | Hyperliquid Strategies Inc | US44916Y1064 | 44916Y106 | 0.464% | $49.8M | Equity (common) | Corporate | United States | USD |
| 94 | Tyra Biosciences Inc | US90240B1061 | 90240B106 | 0.414% | $44.5M | Equity (common) | Corporate | United States | USD |
| 95 | Corvus Pharmaceuticals Inc | US2210151005 | 221015100 | 0.408% | $43.8M | Equity (common) | Corporate | United States | USD |
| 96 | Cullinan Therapeutics Inc | US2300311063 | 230031106 | 0.403% | $43.3M | Equity (common) | Corporate | United States | USD |
| 97 | Precigen Inc | US74017N1054 | 74017N105 | 0.376% | $40.4M | Equity (common) | Corporate | United States | USD |
| 98 | Inhibrx Biosciences Inc | US45720N1037 | 45720N103 | 0.354% | $38.0M | Equity (common) | Corporate | United States | USD |
| 99 | Taysha Gene Therapies Inc | US8776191061 | 877619106 | 0.353% | $37.9M | Equity (common) | Corporate | United States | USD |
| 100 | Ardelyx Inc | US0396971071 | 039697107 | 0.352% | $37.8M | Equity (common) | Corporate | United States | USD |